Press Releases

/Press Releases

Chinese Regulatory Authority [NMPA] Approves IND Application of Oramed’s Oral Insulin Capsules

NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of [...]

2019-03-26T08:40:00+00:00 Categories: Press Releases|Tags: |

Oramed to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place [...]

2019-02-06T08:25:00+00:00 Categories: Press Releases|Tags: |

Oramed Initiates Phase I Oral GLP-1 Study Under IND

JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 [...]

2019-01-22T08:25:00+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals’ CEO Letter to Shareholders

JERUSALEM, Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) Dear Shareholders, We opened the year 2019 with the announcement of our receipt of a $3 million milestone payment from our partners HTIT, thereby increasing our total payments from HTIT received [...]

2019-01-15T08:55:00+00:00 Categories: Press Releases|Tags: |

Oramed Receives Additional $3 Million Milestone Payment from HTIT

Totaling $33 M in payments from HTIT received to date JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received a milestone payment of [...]

2019-01-09T08:40:00+00:00 Categories: Press Releases|Tags: |

Oramed to Present at the Tides Europe 2018 Conference

NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Tides Europe 2018 Conference, EuroPeptides Track, taking [...]

2018-11-05T08:25:00+00:00 Categories: Press Releases|Tags: |

Oramed to Present at Cardiometabolic Health Congress

NEW YORK, Oct. 23, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing two recent Phase IIb studies of its orally ingestible insulin capsule, [...]

2018-10-23T08:25:00+00:00 Categories: Press Releases|Tags: |